Sarepta Halts Development, Testing of DMD Therapy SRP-5051
Clinical development and trial testing of vesleteplirsen (SRP-5051) for Duchenne muscular dystrophy (DMD) was stopped, with the developer citing safety concerns, FDA feedback, and an evolving therapeutic landscape.
Sarepta Therapeutics has discontinued its vesleteplirsen (SRP-5051) development program, a once-promising exon 51–skipping therapy for
According to a recent
Earlier this year, Sarepta reported
However, as the MOMENTUM trial progressed,
The FDA had previously placed a clinical hold on the trial in 2022 after a severe hypomagnesemia case. Although the hold was lifted later that year, allowing the trial to resume with additional safety measures, concerns remained.
“The decision to discontinue this program has no impact on our other approved therapies and/or clinical study programs, including Sarepta’s PMO exon skipping therapies and Sarepta’s gene therapy,” Sarepta said
Parent Project Muscular Dystrophy, a leading nonprofit dedicated to advancing DMD research and care,
“We are grateful to all the families who have participated in clinical trials with vesleteplirsen, and to the Sarepta team for their work to advance therapy development in Duchenne,” the organization said in a news release. “The discontinuation of a trial is always difficult for our community, but we remain hopeful that the data from this trial will inform other potential treatments and that these experiences will lead us to the day that we end Duchenne.”
Participants enrolled in the MOMENTUM trial are being scheduled for final study visits.3
References
1. Sarepta Therapeutics announces third quarter 2024 financial results and recent corporate developments. News release. Sarepta Therapeutics. November 6, 2024. Accessed November 14, 2024. https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-third-quarter-2024-financial
2. Shaw ML. Positive phase 2 data for SRP-5051 in Duchenne muscular dystrophy. AJMC®. February 13, 2024. Accessed November 14, 2024. https://www.ajmc.com/view/positive-phase-2-data-for-srp-5051-in-duchenne-muscular-dystrophy
3. Lobo A. Sarepta stops development of exon 51-skipping therapy for DMD. Muscular Dystrophy News Today. November 12, 2024. Accessed November 14, 2024. https://musculardystrophynews.com/news/sarepta-stops-development-exon-51-skipping-therapy-dmd/
4. Community letter: update SRP-5051 program. Sarepta Therapeutics. November 6, 2024. Accessed November 14, 2024. https://www.sarepta.com/community-letter-update-srp-5051-program
5. Sarepta announces discontinuation of SRP-5051 development for Duchenne. News release. Parent Project Muscular Dystrophy. November 6, 2024. Accessed November 14, 2024. https://www.parentprojectmd.org/sarepta-announces-discontinuation-of-srp-5051-development-for-duchenne/
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- More Effective CKD Strategy Could Have Health, Societal Benefits
September 22nd 2025
- Antifibrotic Therapy Effective for Certain Patients With PPF
September 22nd 2025